1. Introduction {#sec1}
===============

Congestive heart failure is a leading cause of morbidity and mortality with a 20%--30% death rate at 3 years [@bib1], [@bib2], [@bib3]. Cardiac resynchronization therapy (CRT) is an effective adjunctive therapy for many heart failure patients [@bib4], [@bib5]. CRT is achieved by pacing both the right (RV) and left (LV) ventricles with the LV lead usually placed in a branch of the coronary sinus through a transvenous approach [@bib6]. Anatomical challenges occasionally result in failure of LV lead placement during the procedure or in lead dislodgement in the post-operative period, necessitating reoperation for repositioning [@bib7], [@bib8], [@bib9]. The major reasons for reoperation are LV lead dislodgement with loss of capture, phrenic nerve stimulation (PNS), and increased LV pacing thresholds without obvious lead dislodgement [@bib9]. Recently, approved quadripolar LV leads have provided more options for LV pacing, giving operators more choices for LV lead positioning with less compromise in lead stability. It remains however unclear whether these technological advances translate into better procedural or clinical outcomes for CRT recipients. We therefore sought to investigate differences in the rates of combined intra-operative and post-operative LV lead related complications in patients receiving quadripolar versus bipolar LV leads in real-world clinical practice and examine potential differences in longer term clinical outcomes.

2. Methods {#sec2}
==========

This is a single center, observational study comparing differences in patient outcomes after CRT based on the type of the implanted LV lead LV (Quadripolar vs. Bipolar). The study was approved by the Institutional Review Board of the University of Pittsburgh. All patients who had an attempt at CRT defibrillator (CRT-D) or pacemaker (CRT-P) device implantation at the hospitals of the University of Pittsburgh Medical Center (UPMC) between 2011 and 2014 were included in this study. Both *de novo* CRT implantations and upgrades from other devices to CRT were included. Baseline demographic and clinical variables including pre-procedural assessment of left ventricular ejection fraction (EF) were collected. Institutional reports to the National Cardiovascular Data Registry - ICD registry together with the UPMC electronic health records (EHR) were used as sources of information.

The index procedure was the *de novo* or upgrade CRT procedure. Operative notes were reviewed to identify patients with failed attempts at LV lead placement. EHR were reviewed to capture all instances of procedural or LV lead related complications. Outcomes including hospitalization for any reason (device-related complications, heart failure, and arrhythmia) were abstracted from the EHR. Phrenic nerve stimulation (PNS) during follow-up visits was also recorded. Mortality data was obtained from the electronic medical records, including scanned death certificates, as well as from the Social Security Death Index records through October 2015.

The choice of the model and manufacturer of CRT devices and LV leads was left to the discretion of the implanting physician. Quadripolar LV leads included the Food and Drug Administration approved St. Jude Medical (Sylmar, CA) 'Quartet' lead and the Medtronic (Minneapolis, MN) 'Attain Performa' family of leads.

The implantation procedure was performed by electrophysiologists who were experienced in performing CRT procedures. All operators had no less than 3 years of experience in implanting LV leads from different manufacturers. The site of LV pacing was chosen by the implanting physician based on lead stability, the absence of PNS, and favorable pacing parameters. Device programming was at the discretion of the implanting physician. A failed attempt at LV lead placement was defined as abandoned LV lead implantation during the index procedure.

Patients were followed to the primary composite end-point of LV lead implant failure, dislodgment, or LV pacing deactivation for PNS in the first 12 months after the index procedure. Secondary outcomes include all-cause hospitalizations, device-related hospitalizations, hospitalization for arrhythmia, hospitalization for heart failure, and all-cause mortality. Hospitalizations were defined as at least one overnight stay in the hospital under admission or observation status. Patients were followed by the device clinic at UPMC. All patients presented to the clinic 2 weeks after the index procedure for a surgical wound check at the site of device implantation. Their follow-up thereafter consisted of clinic visits every 6 months or clinic visits once a year with scheduled home monitoring downloads every 3 months.

Baseline characteristics were presented as mean ± standard deviation for continuous variables and as n (%) for categorical variables. Differences between patients receiving quadripolar vs. bipolar LV leads were compared using the Student\'s *t*-test and chi-squared tests, respectively. Incidence of time-to-event outcomes was analyzed using Kaplan-Meier analyses and compared between quadripolar and bipolar LV lead recipients using the log-rank test. Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary NC).

3. Results {#sec3}
==========

A total of 1441 patients (292 quadripolar and 1149 bipolar) were implanted with a CRT device between January 2011 to December 2014. They were followed-up for a mean of 609 ± 480 days. Of the overall cohort, 1220 (85%) patients had at lead 1 year of follow-up. [Table 1](#tbl1){ref-type="table"} shows the baseline characteristics of the overall cohort and of the quadripolar vs. bipolar groups. Compared to patients receiving a bipolar LV lead, patients receiving quadripolar leads were younger (70.6 ± 11.4 vs. 72.5 ± 11.6, p = 0.01) and had more Diabetes mellitus (42% versus 33%, p = 0.004). All other baseline characteristics were comparable between the two groups. Among the implanted quadripolar LV leads, 224 were from St. Jude Medical (Sylmar, CA) and 68 from Medtronic (Minneapolis, MN). There were no differences in LV lead complications or patients outcomes by lead model or manufacturer.

There were a total of 28 failed attempts at LV lead placement \[1 (0.3%) in the quadripolar group vs. 27 (2.3%) in the bipolar group, p = 0.029\]. There were no instances of switching from a quadripolar to a bipolar LV lead or *vice versa* during the index procedure. Over 12 months of follow-up, the composite endpoint of LV lead related complications occurred significantly less in the quadripolar compared to the bipolar group \[8 (2.7%) compared to 78 (6.8%), p = 0.009\]. The individual components of the composite end point of LV lead related complications and their rates between the two groups are shown in [Table 2](#tbl2){ref-type="table"}. Although there were no statistically significant differences in the individual components of the composite endpoint of LV lead related complications, except for lead placement failures, the combined composite endpoint was reached significantly less (Hazard Ratio 0.22, 95% Confidence Interval 0.08--0.60, p = 0.001) in quadripolar vs. bipolar LV lead recipients ([Fig. 1](#fig1){ref-type="fig"}).

As shown is [Table 3](#tbl3){ref-type="table"}, there were no statistically significant differences in the secondary endpoints of the study. The rates of mortality and hospitalizations ([Fig. 2](#fig2){ref-type="fig"}) for any cause were comparable between recipients of quadripolar and bipolar LV leads. As shown in [Table 3](#tbl3){ref-type="table"}, there were a total of 79 patients who experienced PNS in the first year after implantation: 65 (5.7%) with bipolar leads and 14 (4.8%) with quadripolar leads. In these patients, 59 of 65 (91%) in the bipolar lead group and 12 of 14 (86%) in the quadripolar lead group had resolution of PNS with adjustment of the pacing settings.

4. Discussion {#sec4}
=============

Our findings demonstrate that the use of quadripolar LV leads reduces the combined intra-operative and post-operative LV lead related complications over a 12 months follow-up period. Judging by the early curve separation demonstrated in [Fig. 1](#fig1){ref-type="fig"}, the superior performance of the quadripolar lead seems to be mainly driven by less intra-operative failures of placement or early post-procedural LV lead dislodgement or deactivation for PNS. The implications of our findings are that quadripolar LV leads, by virtue of the numerous pacing vector options that they provide, allow for higher success rates of LV lead placement in more stable positions, thus translating into fewer lead dislodgements and lead deactivations in follow-up.

Our findings are consistent with some but not all findings from other comparable smaller [@bib10], [@bib11] and larger [@bib12], [@bib13] studies. The randomized MORE-CRT trial [@bib12], [@bib13] showed an increased procedural success and reduced intra- and post-operative complications with the use of quadripolar LV leads. Contrary to the results of previous work however, our study does not show a difference in mortality or rates of hospitalizations for heart failure or PNS in recipients of quadripolar versus bipolar LV leads [@bib11], [@bib14], [@bib15]. It is worth noting however that our study was based exclusively on our institutional records, independent of data sponsored by industry. In addition, our study is the first to look at the combined performance of quadripolar leads from two manufacturers as all prior studies focused on one lead model from a single manufacturer [@bib13], [@bib16]. Lastly, our study has included LV leads implanted with CRT-D and CRT-P devices, unlike all other similar studies that focused exclusively on CRT-D recipients.

Our current study has limitations. First, it is retrospective and therefore may inherently have selection and information bias. The type of LV lead implanted was dependent on operator choice as well as the availability of quadripolar leads in the United States, which started 2011. There is a possibility of selection bias but we have included in our analysis all patients who were implanted with bipolar or quadripolar LV leads over the study period, without any exclusion to minimize bias. Moreover, the baseline clinical characteristics between the two study groups were generally similar. Another limitation is that our study was conducted at a single hospital system, so our results may not be reproducible at other institutions or in other clinical settings. However, it is worth noting that CRT implantation and subsequent management of LV lead-related complications are typically performed at tertiary centers with similar levels of expertise to those available at our institution. In addition, although all operative notes were reviewed and none mention switching LV lead type or shape during the index procedure due to difficult anatomy of other procedural considerations, we cannot exclude that this may have happened but not dictated in the operative note. Lastly, although quadripolar leads were implanted in 292 patients in our study, no patient received LV multipoint pacing.

5. Conclusion {#sec5}
=============

In the real world setting, quadripolar LV leads have significantly lower rates of implantation failure and post-operative lead dislodgement or deactivation. These results which have important clinical implications to CRT recipients need to be validated in larger multicenter data.
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###### 

Pre-Implant Characteristics of N = 1441 patients (2011--2014).

Table 1

                                Overall Cohort   Bipolar        Quadripolar   P-Value
  ----------------------------- ---------------- -------------- ------------- ---------
  Number of Patients            1441             1149           292           
  Age                           72.1 ± 11.6      72.5 ± 11.6    70.6 ± 11.4   0.014
  BMI                           29.5 ± 9.9       29.5 ± 10.6    29.5 ± 6.3    0.932
  Diabetes Mellitus             499 (34.6%)      377 (32.8%)    122 (41.8%)   0.004
  Hypertension                  1059 (73.5%)     840 (73.1%)    219 (75.0%)   0.569
  Prior myocardial Infarction   667 (46.3%)      545 (47.4%)    122 (41.8%)   0.076
  Prior PCI                     355 (24.6%)      285 (24.8%)    70 (24.0%)    0.750
  Prior CABG                    441 (30.6%)      357 (31.1%)    84 (28.8%)    0.429
  Prior Heart Failure           1266 (87.9%)     1011 (88.0%)   255 (87.3%)   0.669
  Prior Heart Failure Hosp.     492 (34.1%)      387 (33.7%)    105 (36.0%)   0.084
  NYHA Class                                                                  0.178
   1                            84 (5.8%)        70 (6.1%)      14 (4.8%)     
   2                            251 (17.4%)      189 (16.4%)    62 (21.2%)    
   3                            791 (54.9%)      639 (55.6%)    152 (52.1%)   
   4                            47 (3.3%)        39 (3.4%)      8 (2.7%)      
  Atrial Fibrillation           756 (52.5%)      616 (53.6%)    140 (47.9%)   0.073
  QRS Width                     150 ± 31.4       150 ± 31.4     150 ± 31.4    0.957
  Creatinine                    1.32 ± 0.88      1.30 ± 0.85    1.37 ± 0.99   0.224
  Pre-Implant LVEF              28.4 ± 11.6      28.4 ± 11.6    28.1 ± 11.3   0.652
  CRT Upgrade Procedure         572 (39.7%)      476 (41.4%)    96 (32.8%)    \<0.001
  Total Follow Up Time (Days)   609 ± 480        698 ± 490      256 ± 189     \<0.001

###### 

Lead placement failure, lead dislodgement, and lead deactivations.

Table 2

                           Overall Cohort   Bipolar     Quadripolar   P-Value
  ------------------------ ---------------- ----------- ------------- ---------
  Number of Patients       1441             1149        292           
  Lead Placement Failure   28 (1.9%)        27 (2.3%)   1 (0.3%)      0.029
  Lead Dislodgement                                                   
   Within 30 Days          24 (1.7%)        23 (2.0%)   1 (0.3%)      0.067
   Within 60 Days          27 (1.9%)        26 (2.3%)   1 (0.3%)      0.028
   Within 90 Days          30 (2.1%)        29 (2.5%)   1 (0.3%)      0.019
   Within 6 Months         37 (2.6%)        33 (2.9%)   4 (1.4%)      0.211
   Within 1 Year           41 (2.8%)        35 (3.0%)   6 (2.1%)      0.435
  Lead Deactivation                                                   
   Within 30 Days          9 (0.6%)         9 (0.8%)    0 (0.0%)      0.218
   Within 60 Days          10 (0.7%)        10 (0.9%)   0 (0.0%)      0.227
   Within 90 Days          12 (0.8%)        12 (1.0%)   0 (0.0%)      0.140
   Within 6 Months         15 (1.0%)        14 (1.2%)   1 (0.3%)      0.329
   Within 1 Year           17 (1.2%)        16 (1.4%)   1 (0.3%)      0.221

###### 

Phrenic nerve stimulation, hospitalizations, and mortality outcomes.

Table 3

                               Full Cohort   Bipolar       Quadripolar   P-Value
  ---------------------------- ------------- ------------- ------------- ---------
  Number of Patients           1441          1149          292           
  Phrenic Nerve Stimulation                                              
   Within 30 Days              51 (3.5%)     43 (3.7%)     8 (2.7%)      0.481
   Within 60 Days              59 (4.1%)     49 (4.3%)     10 (3.4%)     0.620
   Within 90 Days              67 (4.6%)     55 (4.8%)     12 (4.1%)     0.755
   Within 6 Months             74 (5.1%)     61 (5.3%)     13 (4.5%)     0.656
   Within 1 Year               79 (5.5%)     65 (5.7%)     14 (4.8%)     0.666
  HF Hospitalization                                                     
   Within 30 Days              35 (2.4%)     25 (2.2%)     10 (3.4%)     0.206
   Within 60 Days              61 (4.2%)     46 (4.0%)     15 (5.1%)     0.415
   Within 90 Days              82 (5.7%)     64 (5.6%)     18 (6.2%)     0.672
   Within 6 Months             124 (8.6%)    98 (8.5%)     26 (8.9%)     0.815
   Within 1 Year               176 (12.2%)   145 (12.6%)   31 (10.6%)    0.423
  Arrhythmia Hospitalization                                             
   Within 30 Days              18 (1.2%)     13 (1.1%)     5 (1.7%)      0.386
   Within 60 Days              35 (2.4%)     28 (2.4%)     7 (2.4%)      1.000
   Within 90 Days              46 (3.2%)     39 (3.4%)     7 (2.4%)      0.459
   Within 6 Months             66 (4.6%)     58 (5.0%)     8 (2.7%)      0.115
   Within 1 Year               99 (6.9%)     84 (7.3%)     15 (5.1%)     0.242
  Any Hospitalization                                                    
   Within 30 Days              140 (9.7%)    108 (9.4%)    32 (11.0%)    0.438
   Within 60 Days              241 (16.7%)   191 (16.6%)   50 (17.1%)    0.860
   Within 90 Days              296 (20.5%)   243 (21.1%)   53 (18.2%)    0.291
   Within 6 Months             397 (27.6%)   325 (28.3%)   72 (24.7%)    0.240
   Within 1 Year               521 (36.2%)   429 (37.3%)   92 (31.5%)    0.065
  Mortality                                                              
   Within 30 Days              30 (2.1%)     26 (2.3%)     4 (1.4%)      0.490
   Within 60 Days              42 (2.9%)     36 (3.1%)     6 (2.1%)      0.435
   Within 90 Days              52 (3.6%)     46 (4.0%)     6 (2.1%)      0.157
   Within 6 Months             99 (6.9%)     85 (7.4%)     14 (4.8%)     0.121
   Within 1 Year               147 (10.2%)   126 (11.0%)   21 (7.2%)     0.065
